B Capital led a $100m Series A round in Triumvira Immunologics.

B Capital, a multi-stage global investment firm, led a $100m Series A round in Triumvira Immunologics, a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics, with participation from ATEM Capital, Myeloma Investment Fund, Leaps by Bayer, and Northpond Ventures. "We would like to welcome our new investors to our Series A syndicate and acknowledge our current investors for their growing confidence in our technology and approach to empowering the body’s natural defenses against life-threatening solid tumors where there are significant gaps in cell therapies. Our proprietary TAC technology platform offers an innovative approach to developing novel autologous and allogeneic treatments for solid tumors, and we are excited to advance our pipeline through 2022 and beyond," Paul Lammers, Triumvira President and CEO.